Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 6/20 | 0.46 |
| ▸ | ATP4B | P51164 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.46 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | FASN | P49327 | 1/20 | 0.46 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.46 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23988389 | 0.91 | ATP4A (0.58) | ATP4AATP4BALDH1A1MAPTCYP2C9 | |
| SCHEMBL23988282 | 0.90 | RUNX1 (0.52) | ATP4AATP4BALDH1A1MAPTCYP2C9 | |
| SCHEMBL23988364 | 0.89 | ATP4A (0.46) | ATP4AATP4BALDH1A1MAPTCYP2C9 | |
| SCHEMBL23988268 | 0.87 | KDM4E (0.48) | ATP4AATP4BALDH1A1MAPTCYP2C9 | |
| SCHEMBL23988378 | 0.85 | CYP2C9 (0.40) | ATP4AATP4BALDH1A1MAPTCYP2C9 | |
| SCHEMBL23988276 | 0.84 | ALDH1A1 (0.40) | ATP4AATP4BALDH1A1MAPTCYP2C9 | |
| SCHEMBL23988422 | 0.82 | KMT2A (0.49) | ATP4AATP4BALDH1A1MAPTCYP2C9 | |
| SCHEMBL23988277 | 0.81 | ATP4A (0.49) | ATP4AATP4BALDH1A1MAPTCYP2C9 | |
| SCHEMBL23988595 | 0.81 | ATP4A (0.58) | ATP4AATP4BALDH1A1MAPTCYP2C9 | |
| SCHEMBL23988352 | 0.80 | KMT2A (0.53) | ATP4AATP4BALDH1A1MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202796-A1 | CXCL10 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-06-30 | — | — | US | disclosed |
| US-20210338650-A1 | CXCL10 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202796-A1 | CXCL10 Inhibitors | CXCL10, CCL5, CCL11 | ATP4A 4581/4885ATP4B 4629/4885ALDH1A1 3507/4885 |
| US-20210338650-A1 | CXCL10 Inhibitors | CXCL10, CCL5, CCL11 | ATP4A 4581/4885ATP4B 4629/4885ALDH1A1 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.